REG - Renalytix PLC - Additional Subscription for 11m Shares

RenalytixAnnouncement

24/09/2025 10:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250924:nRSX6328Aa&default-theme=true

RNS Number : 6328A  Renalytix PLC  24 September 2025

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED TO CONSTITUTE
INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATIONS (EU) NO.
596/2014 WHICH FORMS PART OF UK LAW BY VIRTUE OF THE EUROPEAN UNION
(WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT
THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

24 September 2025

 

Renalytix plc

("Renalytix" or the "Company")

 

Additional Institutional Subscription for 11 million Shares

 

Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine company
with kidneyintelX.dkd, the only FDA-approved and Medicare reimbursed
prognostic test to support early-stage risk assessment in chronic kidney
disease, announces that, further to the Company's announcements dated 22
September 2025 regarding the Placing and Subscription which raised gross
proceeds of £5.20 million, the Company has entered into an additional
subscription agreement following inbound interest from a new institutional
investor (the "Additional Subscription").

 

Pursuant to the terms of the Additional Subscription Agreement, ABRDN World
Healthcare Fund has subscribed for 11,000,000 Subscription Shares at the Issue
Price of 9.5 pence per share (the "Additional Subscription Shares") for an
aggregate Subscription of £1.045 million ($1.410 million).

 

The funds raised via the Additional Subscription will further support the
Company's commercial distribution efforts, which includes the recently
announced collaboration with Tempus AI, Inc. (NASDAQ: TEM).

 

James McCullough, CEO of Renalytix, commented: "We are particularly pleased
with the strong institutional support we have received at this critical time
for accelerating growth with our U.S. kidneyintelX.dkd prognostic testing and
unique data accumulation program in diabetes and kidney disease."

 

Admission and Total Voting Rights

Application will be made to the London Stock Exchange for the Additional
Subscription Shares to be admitted to trading on the AIM. It is expected that
Admission of the Additional Subscription Shares will become effective and that
dealings in the Additional Subscription Shares will commence at 8.00 a.m. on
Monday 29 September 2025, the same day as the 45,487,903 Second Tranche
Placing Shares. This will follow the Admission of the 9,253,679 First Tranche
Placing Shares on Friday 26 September 2025. The Retail Offer Shares are also
expected to be admitted to trading on AIM on Monday 29 September 2025.

 

The Additional Subscription Shares when issued, will be fully paid and will
rank pari passu in all respects with the existing Ordinary Shares, including
the right to receive all dividends and other distributions declared, made or
paid after the date of issue.

 

A further announcement will be made regarding the Company's enlarged issued
share capital and Total Voting Rights once the result of the Retail Offer has
been confirmed.

 

Capitalised terms used in this announcement have the meanings given to them in
the Company's 'Proposed Fundraise' and 'Result of Fundraise' announcements
dated 22 September 2025, unless the context provides otherwise.

 

For further information, please contact:

 

 Renalytix Plc                                                             www.renalytix.com (http://www.renalytix.com)

 James McCullough, CEO                                                     Via Walbrook PR

 SP Angel Corporate Finance LLP  (Nominated Adviser and Joint Broker)      Tel: 0203 470 0470

 Jeff Keating / David Hignell (Corporate Finance)

 Vadim Alexandre (Corporate Broking)

 Oberon Capital (Sole Bookrunner and Joint Broker)                         Tel: 020 3179 5300

 Mike Seabrook / Nick Lovering / Aimee McCusker

 Walbrook PR Limited                  Tel: 020 7933 8780 or renalytix@walbrookpr.com

                                    (mailto:renalytix@walbrookpr.com)
 Paul McManus / Alice Woodings

                                      Mob: 07980 541 893 / 07407 804 654

 

The person responsible for making this Announcement on behalf of the Company
is

James McCullogh, Chief Executive Officer.

 

 

Forward-Looking Statements

 

This Announcement includes "forward-looking statements" which includes all
statements other than statements of historical fact, including, without
limitation, those regarding the Company's financial position, business
strategy, plans and objectives of management for future operations, or any
statements preceded by, followed by or that include the words "targets",
"believes", "expects", "aims", "intends", "will", "may", "anticipates",
"would", "could" or similar expressions or negatives thereof. Such
forward-looking statements involve known and unknown risks, uncertainties and
other important factors beyond the Company's control that could cause the
actual results, performance or achievements of the Company to be materially
different from future results, performance or achievements expressed or
implied by such forward-looking statements. Such forward-looking statements
are based on numerous assumptions regarding the Company's present and future
business strategies and the environment in which the Company will operate in
the future. These and other risks are described more fully in the Company's
filings with the SEC, including the "Risk Factors" section of its Annual
Report on Form 10-K filed with the SEC, and other filings the Company makes
with the SEC from time to time. These forward-looking statements speak only as
at the date of this Announcement. The Company expressly disclaims any
obligation or undertaking to disseminate any updates or revisions to any
forward-looking statements contained herein to reflect any change in the
Company's expectations with regard thereto or any change in events, conditions
or circumstances on which any such statements are based unless required to do
so by applicable law or the AIM Rules for Companies.

 

No statement in this Announcement is intended to be a profit forecast and no
statement in this Announcement should be interpreted to mean that earnings per
share of the Company for the current or future financial years would
necessarily match or exceed the historical published earnings per share of the
Company.

 

This Announcement does not constitute a recommendation concerning any
investor's investment decision with respect to the Fundraise. Each investor or
prospective investor should conduct his, her or its own investigation,
analysis and evaluation of the business and data described in this
Announcement and publicly available information.

 

The new Ordinary Shares to be issued pursuant to the Fundraise will not be
admitted to trading on any stock exchange other than the AIM market of the
London Stock Exchange plc.

 

The price and value of Ordinary Shares of the Company can go down as well as
up. Past performance is not a guide to future performance.

 

Neither the content of the Company's website (or any other website) nor the
content of any website accessible from hyperlinks on the Company's website (or
any other website) is incorporated into, or forms part of, this Announcement.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOEUSSWRVBUKURR